MD23Y - Method of differentiated treatment of non-invasive in situ lobular carcinoma of the mammary gland - Google Patents
Method of differentiated treatment of non-invasive in situ lobular carcinoma of the mammary gland Download PDFInfo
- Publication number
- MD23Y MD23Y MDS20080028A MDS20080028A MD23Y MD 23 Y MD23 Y MD 23Y MD S20080028 A MDS20080028 A MD S20080028A MD S20080028 A MDS20080028 A MD S20080028A MD 23 Y MD23 Y MD 23Y
- Authority
- MD
- Moldova
- Prior art keywords
- cancer
- hormone therapy
- postoperative period
- mastectomy
- case
- Prior art date
Links
- 210000005075 mammary gland Anatomy 0.000 title claims abstract description 11
- 238000011065 in-situ storage Methods 0.000 title claims abstract description 8
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title claims description 5
- 208000000265 Lobular Carcinoma Diseases 0.000 title abstract description 3
- 201000003714 breast lobular carcinoma Diseases 0.000 title abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 28
- 201000011510 cancer Diseases 0.000 claims abstract description 24
- 238000001794 hormone therapy Methods 0.000 claims abstract description 19
- 230000002980 postoperative effect Effects 0.000 claims abstract description 18
- 238000001959 radiotherapy Methods 0.000 claims abstract description 9
- 238000002271 resection Methods 0.000 claims abstract description 8
- 238000009607 mammography Methods 0.000 claims abstract description 5
- 230000004807 localization Effects 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 201000004933 in situ carcinoma Diseases 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 201000011059 lobular neoplasia Diseases 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229960001603 tamoxifen Drugs 0.000 description 4
- 201000005389 breast carcinoma in situ Diseases 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 208000004434 Calcinosis Diseases 0.000 description 2
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 2
- 238000002555 auscultation Methods 0.000 description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 2
- 239000000082 organ preservation Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010057687 Bloody discharge Diseases 0.000 description 1
- 208000035211 Heart Murmurs Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000008508 epithelial proliferation Effects 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
Inventia se refera la medicina, in special la oncologia glandei mamare si poate fi utilizata pentru tratamentul diferentiat al carcinomului lobular in situ neivaziv al glandei mamare. Esenta inventiei consta in aceea ca se determina morfologic prezenta de cancer lobular si se efectueaza mamografia, si in cazul in care se determina cancer cu un singur focar, se efectueaza rezectie sectoriala cu radioterapie si hormonoterapie in perioada postoperatorie. In cazul cancerului multifocal, si anume cu focare in acelasi cadran cu o distanta de 4…5 cm intre ele se efectueaza rezectie sectoriala sau mastectomie cu hormonoterapie in perioada postoperatorie. In cazul cancerului multicentric cu focare in diferite cadrane sau cu mai mult de 5 cm intre ele se efectueaza mastectomie cu hormonoterapie in perioada postoperatorie si in cazul cancerului cu localizarea focarelor in ambele glande mamare se efectueaza mastectomie cu radioterapie si hormonoterapie in perioada postoperatorie. The invention relates to medicine, in particular to mammary gland oncology and may be used for the differential treatment of non-invasive in situ lobular carcinoma of the mammary gland. The essence of the invention is that the presence of lobular cancer is morphologically determined and mammography is performed, and if single-target cancer is determined, sectoral resection with radiotherapy and hormone therapy is performed in the postoperative period. In the case of multifocal cancer, namely with outbreaks in the same quadrant with a distance of 4 ... 5 cm between them is performed sectoral resection or mastectomy with hormone therapy in the postoperative period. In the case of multicentric cancer with outbreaks in different quadrants or more than 5 cm apart, a mastectomy with hormone therapy is performed in the postoperative period and in the case of cancer with focal localization in both mammary glands, a mastectomy with radiotherapy and hormone therapy is performed in the postoperative period.
Description
Invenţia se referă la medicină, în special la oncologia glandei mamare şi poate fi utilizată pentru tratamentul diferenţiat al carcinomului lobular in situ neivaziv al glandei mamare. The invention relates to medicine, in particular to breast oncology and can be used for the differentiated treatment of non-invasive lobular carcinoma in situ of the breast.
Este cunoscută metoda de tratament al carcinomului lobular in situ (CLIS), care constă în efectuarea hormonoterapiei antiestrogene cu tamoxifen, un tratament care ar scădea riscul de apariţie a cancerului invaziv la pacientele diagnosticate cu CLIS. Datele preliminare demonstrează o scădere cu 49% a riscului de apariţie a cancerului mamar invaziv, atât la pacientele mai tinere de 50 ani, cât şi la cele peste această vârstă, prin utilizarea tamoxifenului timp de 5 ani [1]. The treatment of lobular carcinoma in situ (LCIS) is known to involve antiestrogen hormone therapy with tamoxifen, a treatment that would reduce the risk of invasive cancer in patients diagnosed with LCIS. Preliminary data demonstrate a 49% reduction in the risk of invasive breast cancer, both in patients younger than 50 years and in those over this age, by using tamoxifen for 5 years [1].
Dezavantajul constă în aceea că acest tratament are efect numai la pacientele cu receptori estrogenici pozitivi. Totodată, se recomandă ca aceste paciente să fie urmărite prin examen clinic odată la 4…6 luni şi anual să se efectueze o mamografie. Controalele frecvente trebuie efectuate toată viaţa, datorită riscului sporit de apariţie a unui cancer invaziv, care rămâne permanent. The disadvantage is that this treatment is only effective in patients with positive estrogen receptors. It is also recommended that these patients be followed up with a clinical examination every 4-6 months and a mammogram every year. Frequent check-ups should be performed throughout life, due to the increased risk of developing invasive cancer, which remains permanent.
Este cunoscută metoda de tratament al carcinomului lobular in situ (CLIS), care constă în efectuarea mastectomiei simple profilactice bilaterale, preferabil urmată de un procedeu de reconstrucţie mamară imediată. Deoarece nu există riscul metastazelor ganglionare regionale, limfadenectomia axilară nu este recomandată [2]. The treatment of lobular carcinoma in situ (LCIS) is known to consist of simple prophylactic bilateral mastectomy, preferably followed by immediate breast reconstruction. Since there is no risk of regional lymph node metastases, axillary lymphadenectomy is not recommended [2].
Dezavantajele constau în aceea că nu toate formele de carcinom lobular necesită efectuarea mastectomiei, care provoacă dereglări estetice şi psihice la pacientele tinere. The disadvantages are that not all forms of lobular carcinoma require mastectomy, which causes aesthetic and psychological disorders in young patients.
Problema pe care o rezolvă invenţia constă în elaborarea unei metode de determinare a tacticii de tratament al carcinomului neinvaziv lobular in situ al glandei mamare pentru efectuarea unui tratament eficient pentru fiecare formă de cancer în parte, pentru a micşora numărul de recidive în formele cu o rată înaltă de apariţie a recidivelor, pentru un tratament cosmetic eficient în unele forme care permit păstrarea organului, pentru eficientizarea triajului femeilor primar stabilite cu carcinom neinvaziv pentru un tratament eficient şi pentru evitarea cheltuielilor şi a timpului pentru investigaţii suplimentare, care duce la micşorarea termenului de spitalizare. The problem solved by the invention consists in developing a method for determining the treatment tactics of non-invasive lobular carcinoma in situ of the mammary gland for performing an effective treatment for each form of cancer, for reducing the number of relapses in forms with a high rate of recurrence, for an effective cosmetic treatment in some forms that allow organ preservation, for streamlining the triage of women primarily diagnosed with non-invasive carcinoma for an effective treatment and for avoiding expenses and time for additional investigations, which leads to a reduction in the length of hospitalization.
Esenţa invenţiei constă în aceea că se determină morfologic prezenţa de cancer lobular şi se efectuează mamografia, şi în cazul în care se determină cancer cu un singur focar, se efectuează rezecţie sectorială cu radioterapie şi hormonoterapie în perioada postoperatorie. În cazul cancerului multifocal, şi anume cu focare în acelaşi cadran cu o distanţă de 4…5 cm între ele, se efectuează rezecţie sectorială sau mastectomie cu hormonoterapie în perioada postoperatorie. În cazul cancerului multicentric cu focare în diferite cadrane sau cu mai mult de 5 cm între ele, se efectuează mastectomie cu hormonoterapie în perioada postoperatorie şi în cazul cancerului cu localizarea focarelor în ambele glande mamare, se efectuează mastectomie cu radioterapie şi hormonoterapie în perioada postoperatorie. The essence of the invention is that the presence of lobular cancer is morphologically determined and mammography is performed, and in case of cancer with a single focus, sectoral resection with radiotherapy and hormone therapy is performed in the postoperative period. In the case of multifocal cancer, namely with foci in the same quadrant with a distance of 4…5 cm between them, sectoral resection or mastectomy with hormone therapy is performed in the postoperative period. In the case of multicentric cancer with foci in different quadrants or with more than 5 cm between them, mastectomy with hormone therapy is performed in the postoperative period and in case of cancer with localization of foci in both mammary glands, mastectomy with radiotherapy and hormone therapy is performed in the postoperative period.
Rezultatul invenţiei constă în eficientizarea tratamentului pentru carcinomul lobular in situ, micşorarea numărului de recidive în formele cu o rată înaltă de apariţie a recidivelor, un tratament cosmetic eficient în unele forme care permit păstrarea organului, eficientizarea triajului femeilor primar stabilite cu carcinom neinvaziv cu efectuarea tratamentului eficient şi evitarea cheltuielilor şi a timpului pentru investigaţii suplimentare, care duce la micşorarea termenului de spitalizare. The result of the invention consists in making the treatment for lobular carcinoma in situ more efficient, reducing the number of relapses in forms with a high rate of relapses, an effective cosmetic treatment in some forms that allow organ preservation, making the triage of women with primary non-invasive carcinoma more efficient by performing effective treatment and avoiding expenses and time for additional investigations, which leads to a reduction in the length of hospitalization.
Avantajele prezentei invenţii constau în determinarea rapidă a tacticii de tratament a carcinomului neinvaziv lobular in situ, ceea ce duce la micşorarea numărului de recidive în formele cu o rată înaltă de apariţie a recidivelor, pentru unele forme care permit păstrarea organului se efectuează un tratament cosmetic eficient, efectuarea unui triaj eficient al femeilor primar stabilite cu carcinom neinvaziv cu stabilirea rapidă a tacticii de tratament, a cheltuielilor şi a timpului necesar pentru investigaţii suplimentare, care duce la micşorarea termenului de spitalizare. The advantages of the present invention consist in the rapid determination of the treatment tactics of non-invasive lobular carcinoma in situ, which leads to a decrease in the number of relapses in forms with a high recurrence rate, for some forms that allow the preservation of the organ, an effective cosmetic treatment is performed, performing an effective triage of women primarily established with non-invasive carcinoma with the rapid establishment of the treatment tactics, the expenses and the time required for additional investigations, which leads to a decrease in the length of hospitalization.
Carcinomul lobular in situ pentru prima dată a fost descris de către Foote şi Stewart în 1941 şi denumit de către Muir cancer acinar (Mihai Andrei Mureşean. Chirurgie oncologică. Cluj-Napoca, vol. 1, 2001). CLIS, în concepţia lui Haagensen (1971), histologic se caracterizează printr-o proliferare epitelială intralobulară masivă, dar neinfiltrativă. Arhitectura lobulară este păstrată, iar celulele prezintă o morfologie omogenă, cu mitoze rare şi fără necroză. Apare cu predilecţie la femei în premenopauză, după care poate regresa sau chiar dispărea. Din aceste motive autorul propune denumirea de “neoplazie lobulară ”. Faţă de CDIS, CLIS este o afecţiune de 6 ori mai rară. C.D.Haagensen la examinarea 10 000 paciente cu tumori benigne a depistat CLIS la 2,7%. Spre deosebire de CDIS, CLIS nu se manifestă prin tumoare palpabilă, eliminări sangvinolente din mamelon, nu are anumite particularităţi mamografice. Deosebim două tipuri de bază CLIS: solid şi glandular. Cel mai frecvent întâlnim forma solidă. Lobular carcinoma in situ was first described by Foote and Stewart in 1941 and named by Muir acinar cancer (Mihai Andrei Mureşean. Chirurgie oncologică. Cluj-Napoca, vol. 1, 2001). CLIS, in Haagensen's (1971) conception, is histologically characterized by a massive, but non-infiltrative intralobular epithelial proliferation. The lobular architecture is preserved, and the cells present a homogeneous morphology, with rare mitoses and no necrosis. It occurs predominantly in premenopausal women, after which it may regress or even disappear. For these reasons, the author proposes the name "lobular neoplasia". Compared to DCIS, CLIS is a condition 6 times rarer. C.D. Haagensen, when examining 10,000 patients with benign tumors, detected CLIS at 2.7%. Unlike DCIS, CLIS does not manifest itself as a palpable tumor, bloody discharge from the nipple, and does not have certain mammographic features. We distinguish two basic types of CLIS: solid and glandular. The solid form is most frequently encountered.
Cu mult mai complicată este depistarea CLIS. Această formă nu se manifestă nici clinic, nici macroscopic, la mamografie în majoritatea cazurilor nu se depistează calcinate, iar dacă sunt, atunci în 60% microcalcificării se supune nu însăşi tumoarea, dar ţesuturile adiacente, uneori la o distanţă considerabilă de la focarul primar. CLIS este o leziune în care multifocalitatea şi multicentricitatea este frecvent întâlnită. Multicentricitatea se constată în 60…80% din cazuri, procentul crescând cu numărul secţiunilor realizate. CLIS este descoperit şi în sânul contralateral în 50…90% din cazuri (Нейштадт Э., Воробьева О. Патология молочной железы , Санкт-Петербург, 2003, p 44-60). Much more complicated is the detection of CLIS. This form does not manifest itself either clinically or macroscopically, in mammography in most cases calcifications are not detected, and if they are, then in 60% of cases, not the tumor itself, but the adjacent tissues, sometimes at a considerable distance from the primary focus, are subjected to microcalcification. CLIS is a lesion in which multifocality and multicentricity are frequently encountered. Multicentricity is found in 60…80% of cases, the percentage increasing with the number of sections performed. CLIS is also discovered in the contralateral breast in 50…90% of cases (Neyshtadt E., Vorob'eva O. Pathology of the Breast, Saint Petersburg, 2003, p 44-60).
Metoda se efectuează în modul următor. The method is performed in the following way.
Pacientelor primar stabilite cu suspecţii de carcinom neinvaziv in situ se efectuează examenul morfologic şi diagnosticarea imagistică. În cazul în care se determină cancer cu un singur focar, se efectuează rezecţie sectorială cu radioterapie şi hormonoterapie în perioada postoperatorie. În cazul cancerului multifocal, şi anume cu focare în acelaşi cadran cu o distanţă de 4…5 cm între ele, se efectuează rezecţie sectorială sau mastectomie cu hormonoterapie în perioada postoperatorie. În cazul cancerului multicentric cu focare în diferite cadrane sau cu mai mult de 5 cm între ele, se efectuează mastectomie cu hormonoterapie în perioada postoperatorie şi în cazul cancerului cu localizarea focarelor în ambele glande mamare, se efectuează mastectomie cu radioterapie şi hormonoterapie în perioada postoperatorie. Patients with primary established suspicions of non-invasive carcinoma in situ undergo morphological examination and imaging diagnostics. If cancer is determined to be single-focal, sectoral resection with radiotherapy and hormone therapy is performed in the postoperative period. In the case of multifocal cancer, namely with foci in the same quadrant with a distance of 4…5 cm between them, sectoral resection or mastectomy with hormone therapy is performed in the postoperative period. In the case of multicentric cancer with foci in different quadrants or more than 5 cm between them, mastectomy with hormone therapy is performed in the postoperative period and in the case of cancer with foci in both mammary glands, mastectomy with radiotherapy and hormone therapy is performed in the postoperative period.
Radioterapia se efectuează în doză de 45…50 Gy pe parcursul a 5...6 săptămâni (câte 8 Gy în săptămână). Radiotherapy is performed in a dose of 45...50 Gy over 5...6 weeks (8 Gy per week).
Hormonoterapia în perioada postoperatorie se efectuează cu Tamoxifen. Hormone therapy in the postoperative period is performed with Tamoxifen.
Exemplu de realizare Example of implementation
La pacienta A., în vârstă de 32 ani, la examenul profilactic s-a depistat o tumoare în glanda mamară pe dreapta. La mamografie s-a depistat cancer lobular, formă solidă multicentrică cu multicalcificări în ţesuturile adiacente în glanda mamară pe dreapta. In patient A., aged 32, a tumor was detected in the right mammary gland during a routine examination. Mammography revealed lobular cancer, a solid multicentric form with multicalcifications in the adjacent tissues in the right mammary gland.
Starea generală a pacientei la internare - satisfăcătoare. Anamnestic: nu se consideră bolnavă. La examenul obiectiv general: aparatul respirator - stare normostenică, sunet pulmonar la percuţie, auscultativ murmur vezicular prezent în ambele câmpuri pulmonare; cordul - limitele absolute şi relative ale matităţii cardiace în normă, auscultativ zgomotele cardiace ritmice cu suflu diastolic la auscultaţia valvulei mitrale; aparatul digestiv - ficat, splină nepalpabile, abdomenul moale, indolor la palpare. Investigaţie paraclinică - indicii hematologici în limitele normei. Pacienta a fost supusă tratamentului conform metodei descrise în invenţie. The patient's general condition upon admission - satisfactory. History: she is not considered sick. On general objective examination: respiratory system - normostenic condition, lung sound on percussion, vesicular murmur present in both lung fields on auscultation; heart - absolute and relative limits of cardiac dullness within normal limits, rhythmic heart sounds with diastolic murmur on auscultation of the mitral valve; digestive system - liver, spleen not palpable, soft abdomen, painless on palpation. Paraclinical investigation - hematological indices within normal limits. The patient was treated according to the method described in the invention.
La examenul histopatologic: carcinom lobular neinvaziv in situ, formă solidă. Pacienta a fost supusă intervenţiei chirurgicale de mastectomie cu efectuarea hormonoterapiei cu tamoxifen în perioada postoperatorie. Pacienta a fost externată în stare satisfăcătoare şi examinată periodic pe parcursul a 5 ani, recidive nu au fost depistate. Histopathological examination: non-invasive lobular carcinoma in situ, solid form. The patient underwent mastectomy surgery with hormone therapy with tamoxifen in the postoperative period. The patient was discharged in satisfactory condition and examined periodically for 5 years, no relapses were detected.
1. Mihai Andrei Mureşean. Chirurgie oncologică. Vol. 1, Cluj-Napoca, 2001 1. Mihai Andrei Mureşean. Oncological Surgery. Vol. 1, Cluj-Napoca, 2001
2. Нейштадт Э., Воробьева О. Патология молочной железы. Санкт-Петербург, 2003, p 44-60 2. Neystadt E., Vorob'eva O. Pathology of the breast. Saint Petersburg, 2003, p 44-60
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20080028A MD23Z (en) | 2008-12-02 | 2008-12-02 | Method of differential treatment of noninvasive lobular mammary carcinoma in situ |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20080028A MD23Z (en) | 2008-12-02 | 2008-12-02 | Method of differential treatment of noninvasive lobular mammary carcinoma in situ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD23Y true MD23Y (en) | 2009-05-31 |
| MD23Z MD23Z (en) | 2010-01-31 |
Family
ID=40901763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20080028A MD23Z (en) | 2008-12-02 | 2008-12-02 | Method of differential treatment of noninvasive lobular mammary carcinoma in situ |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD23Z (en) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD106C2 (en) * | 1993-11-12 | 1995-06-30 | Онкологический Институт Республики Молдова | Method of treatment for mamma cancer |
| MD446G2 (en) * | 1995-07-07 | 1996-11-30 | Онкологический Институт Республики Молдова | Method for mamma cancer treatment |
| US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| CA2219070C (en) * | 1996-10-30 | 2007-12-18 | Eli Lilly And Company | Methods of preventing breast cancer |
| MD798G2 (en) * | 1996-11-15 | 1998-05-31 | Онкологический Институт Республики Молдова | Method of the mamma cancer treatment |
| MD962G2 (en) * | 1997-07-24 | 1998-12-31 | Онкологический Институт Республики Молдова | Method for radical mastectomy |
| EE04873B1 (en) * | 1997-08-29 | 2007-08-15 | Biogen, Incorporated | Use of a viral vector containing a gene encoding an interferon-beta protein and a viral vector with replication deficiencies |
| CN1224431C (en) * | 1997-11-28 | 2005-10-26 | 松浦优之 | Method of wave therapy and apparatus therefor |
| US6333348B1 (en) * | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
| MD1630G2 (en) * | 1999-06-04 | 2001-09-30 | Онкологический Институт Республики Молдова | Method of radical mastectomy in breast cancer |
| UA74798C2 (en) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors |
| MD1569G2 (en) * | 1999-12-17 | 2001-06-30 | Онкологический Институт Республики Молдова | Method of treatment of breast canceeeer in the preoperation period |
| GB0005257D0 (en) * | 2000-03-03 | 2000-04-26 | Pharmacia & Upjohn Spa | Breast cancer hormonal therapy |
| GB0015446D0 (en) * | 2000-06-23 | 2000-08-16 | Pharmacia & Upjohn Spa | Combined therapy against tumors comprising substituted acryloyl distamycin derivates,taxanes and/or antimetabolites |
| GB0015444D0 (en) * | 2000-06-23 | 2000-08-16 | Pharmacia & Upjohn Spa | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors |
| GB0015447D0 (en) * | 2000-06-23 | 2000-08-16 | Pharmacia & Upjohn Spa | Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents |
| US6576612B1 (en) * | 2000-10-02 | 2003-06-10 | Pharmacia Italia S.P.A. | Antitumor therapy comprising distamycin derivatives |
| MD2849G2 (en) * | 2005-05-16 | 2006-04-30 | Василе ЖОВМИР | Method of mammary cancer treatment to patients of old age |
| MD3248G2 (en) * | 2006-06-30 | 2007-09-30 | Василе ЖОВМИР | Method of mammary cancer treatment |
| MD3671G2 (en) * | 2007-11-02 | 2009-09-30 | Онкологический Институт Республики Молдова | Method of subtotal mastectomy in the mammary upper dial cancer |
| MD3772G2 (en) * | 2008-05-12 | 2009-07-31 | Общественное Медико-Санитарное Учреждение Онкологический Институт | Method for treating mammary cancer with metastases |
-
2008
- 2008-12-02 MD MDS20080028A patent/MD23Z/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MD23Z (en) | 2010-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stomper et al. | Mammographic detection of recurrent cancer in the irradiated breast | |
| Caruso et al. | Nipple sparing subcutaneous mastectomy: sixty-six months follow-up | |
| Gumport et al. | Treatment of 126 cases of malignant melanoma: Long term results | |
| Teshome | Role of Operative | |
| Mandrekas et al. | Fat necrosis following breast reduction | |
| Zippel et al. | Delayed breast cellulitis following breast conserving operation | |
| Tinnemans et al. | Multicentricity in nonpalpable breast carcinoma and its implications for treatment | |
| MD23Y (en) | Method of differentiated treatment of non-invasive in situ lobular carcinoma of the mammary gland | |
| Gedam et al. | Clinical presentation and management of locally advanced breast carcinoma | |
| Tan et al. | Breast-conserving surgery for breast cancer | |
| Pinar et al. | The strain and hopelessness in family caregivers of patients with gynecologic cancer receiving chemotherapy | |
| Sikov | Locally advanced breast cancer | |
| McGarry et al. | Triple-negative breast cancer: What crucial information can imaging add to the diagnosis, treatment and prognosis | |
| Moreno et al. | Primary cutaneous adenoid cystic carcinoma in the trunk: case report and literature review | |
| Cusick et al. | Merkel cell carcinoma of the breast: report of a case and review of the literature | |
| Alvarez et al. | 118P Should DIBH (deep inspiration breath-hold) be the standard of care in LBC (left breast cancer)? | |
| MD36Y (en) | Method of differentiated treatment of non-invasive ductal carcinoma of the mammary gland | |
| Saito et al. | The surgical treatment of irradiated wounds: a report on 36 patients | |
| Cantürk et al. | Unexpected Clinical Status of Phyllodes Tumor of the Breast: Massive Bleeding | |
| KP | 116P Is young age an independent adverse prognostic factor in carcinoma breast? A single institute retrospective comparative study from South India | |
| MD24Y (en) | Method of differentiated treatment of non-invasive carcinoma of the mammary gland | |
| Ng et al. | Radical mastectomy of massive stage IV triple negative breast cancer to improve hygiene and comfort in a 90-year-old woman | |
| Cunha et al. | Primary leiomyosarcoma of the breast papilla: a case report | |
| Savage et al. | Lateral Intercostal Artery Perforator Flap to Treat Pure Cutaneous Recurrence After Breast-Conserving Surgery: A Case Report | |
| Zaichuk et al. | The giant phyllodes tumor of the breast—a case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |